Xencor, Inc.

NASDAQ:XNCR

21.26 (USD) • At close November 1, 2024
Bedrijfsnaam Xencor, Inc.
Symbool XNCR
Munteenheid USD
Prijs 21.26
Beurswaarde 1,486,652,272
Dividendpercentage 0%
52-weken bereik 15.31 - 26.84
Industrie Biotechnology
Sector Healthcare
CEO Dr. Bassil I. Dahiyat Ph.D.
Website https://www.xencor.com

An error occurred while fetching data.

Over Xencor, Inc.

Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic

Vergelijkbare Aandelen

ModivCare Inc. logo

ModivCare Inc.

MODV

16.18 USD

Ligand Pharmaceuticals Incorporated logo

Ligand Pharmaceuticals Incorporated

LGND

110.04 USD

Addus HomeCare Corporation logo

Addus HomeCare Corporation

ADUS

126.27 USD

Establishment Labs Holdings Inc. logo

Establishment Labs Holdings Inc.

ESTA

45.42 USD

ImmunityBio, Inc. logo

ImmunityBio, Inc.

IBRX

5.28 USD

Krystal Biotech, Inc. logo

Krystal Biotech, Inc.

KRYS

176.39 USD

Travere Therapeutics, Inc. logo

Travere Therapeutics, Inc.

TVTX

17.57 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)